Azithromycin in upper respiratory tract infections: a clinical trial in children with otitis media

Scand J Infect Dis Suppl. 1992:83:22-5.

Abstract

Azithromycin is a newly developed azalide antibiotic which is very active against microbes causing respiratory tract infections; tissue concentrations remain elevated for a long time after discontinuation of treatment. A clinical study was conducted to compare azithromycin (10 mg/kg administered as a single daily dose for 3 days) with amoxycillin/clavulanic acid (50 mg/kg/day given b.i.d. for 10 days) in 30 children with otitis media. Sensitivity testing demonstrated good azithromycin activity against beta-haemolytic streptococci, Moraxella catarrhalis, Haemophilus influenzae and Staphylococcus aureus. By day 12, clinical cure was recorded in 14/15 children treated with azithromycin and this was maintained at day 30. In the day 12 and 13/15 children by day 30. It was concluded that a 3-day azithromycin regimen produces a satisfactory clinical response and the eradication of key pathogens, and was acceptable for children.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Amoxicillin / therapeutic use
  • Azithromycin
  • Child
  • Child, Preschool
  • Clavulanic Acid
  • Clavulanic Acids / therapeutic use
  • Drug Administration Schedule
  • Drug Therapy, Combination / therapeutic use
  • Erythromycin / analogs & derivatives*
  • Erythromycin / therapeutic use
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Male
  • Otitis Media / drug therapy*
  • Otitis Media / microbiology
  • Otitis Media with Effusion / drug therapy*
  • Otitis Media with Effusion / microbiology

Substances

  • Clavulanic Acids
  • Clavulanic Acid
  • Erythromycin
  • Amoxicillin
  • Azithromycin